Short answer
CG Oncology, Inc. (CGON) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1M with net income of −$79M.
Q2 2026 key financials · XBRL
- Revenue
- $1M
- +6.8% QoQ
- Net income
- −$79M
- −90.8% YoY · −31.3% QoQ
- Operating margin
- -7467.7%
- EPS (diluted)
- −$0.90
- −63.6% YoY · −26.8% QoQ
Source: XBRL data from the CG Oncology, Inc. (CGON) Q2 2026 10-Q on SEC EDGAR. USD.
CG Oncology, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors disclosed in the 2025 Annual Report filed February 27, 2026
- Carried-forward clinical-development risk for cretostimogene and related research programs
- Carried-forward manufacturing risk involving contract supply of cretostimogene
- IPO proceeds fully used by June 30, 2026 for corporate, development, manufacturing, and pre-commercial activities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CG Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.